DDInter1251 DDInter1376
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995. In addition to the above uses, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases. Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does not cause nephrotoxicity or fibrosis.[A180799,A180805] Previously, mycophenolic acid
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Mycophenolate mofetil {u} (Compound) resembles {v} (Compound) Mycophenolic acid
Mycophenolate mofetil {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
Mycophenolate mofetil {u} (Compound) binds {v} (Gene) UGT1A10
Mycophenolate mofetil {u} (Compound) upregulates {v} (Gene) FAM63A
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) HJURP
Mycophenolate mofetil {u} (Compound) causes {v} (Side Effect) Furunculosis
Mycophenolate mofetil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acyclovir
Mycophenolate mofetil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Theophylline
Mycophenolate mofetil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metronidazole
Mycophenolate mofetil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound)
Mycophenolate mofetil (Compound) treats systemic lupus erythematosus (Disease)
Mycophenolate mofetil (Compound) binds UGT1A10 (Gene)
Mycophenolate mofetil (Compound) upregulates FAM63A (Gene)
Mycophenolate mofetil (Compound) downregulates HJURP (Gene)
Mycophenolate mofetil (Compound) causes Furunculosis (Side Effect)
Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Acyclovir
Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Theophylline
Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole
Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Anakinra